Skip to main content
Caplight Logo









EndoGene.Bio

EndoGene.Bio

Private
ParisHealthcare & Life Scienceshttps://endogene.bio/

Last Round

Grant

Jun 15, 2026

Total Funding Raised

$1.95M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

EndoGene.Bio is a biotechnology company that is developing a precision medicine platform using menstrual blood to create non-invasive diagnostics and tools for patient stratification for uterine diseases like endometriosis.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

endometriosis diagnosisnon-invasive diagnosticsprecision medicinepatient stratificationepigenetic biomarkersdrug discoveryfemtechbiological data platformmenstrual blood analysismachine learning diagnosticsclinical trial supportuterine healthtarget identificationwomen's healthcomputational modelingDNA methylation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

EndoGene.Bio Comparables

Compare EndoGene.Bio with similar companies based on industry and business-model similarity.

EndoGene.Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
NextGen Jane
79%
Endodiag
78%
DotLab
78%

EndoGene.Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 15, 2026
SeedFeb 1, 2025

Key People

Founding team and executive leadership

María Teresa Pérez Zaballos

Chief Executive Officer

Executive Team

EndoGene.Bio Investors

Notable investors and investment history

EndoGene.Bio investors
InvestorRounds
GenopoleSeed
Hello TomorrowGrant
Entrepreneurs FirstSeed, Accelerator
BpifranceSeed
Frontline VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 15, 2026

    $107K grant received from Hello Tomorrow.

  • Jan 8, 2026

    Monthly visitors grew 1014% MoM, from 81 to 902.

EndoGene.Bio Filings

Explore SEC and related filing metadata, where available.

EndoGene.Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about EndoGene.Bio's valuation, stock price, and market status.

Is EndoGene.Bio a public or private company?

EndoGene.Bio is a private company.

What is the current stock price of EndoGene.Bio?

EndoGene.Bio is a private company with no public stock price. No recent secondary market data is available.

How much is EndoGene.Bio worth (valuation)?

Valuation information for EndoGene.Bio is not publicly available.

Can I buy EndoGene.Bio stock?

EndoGene.Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was EndoGene.Bio's last funding round?

EndoGene.Bio's most recent funding round was Grant on June 15, 2026.

Who are the main investors in EndoGene.Bio?

Key investors in EndoGene.Bio include Entrepreneurs First.

Will EndoGene.Bio IPO soon?

No public IPO plans have been announced for EndoGene.Bio.

How can I track EndoGene.Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor EndoGene.Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersParis
Employee Range12
Year Founded2022
Last FundingJun 15, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?